在晚期实体瘤患者中评价 FS-8002 的安全性、耐受性、药代动力学、药效动力学、以及初步探索有效性的单臂、开放的 I 期临床试验
[Translation] A single-arm, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of FS-8002 in patients with advanced solid tumors
评价FS-8002 在晚期实体瘤患者中的安全性及耐受性,确定最大耐受剂量(MTD),确定II 期推荐剂量(RP2D)。
[Translation] To evaluate the safety and tolerability of FS-8002 in patients with advanced solid tumors, determine the maximum tolerated dose (MTD), and determine the recommended Phase II dose (RP2D).
100 Clinical Results associated with Huapu Shijiazhuang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Huapu Shijiazhuang Pharmaceutical Co., Ltd.
100 Deals associated with Huapu Shijiazhuang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Huapu Shijiazhuang Pharmaceutical Co., Ltd.